Relmada Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 0.06
Market capitalization 138.16M
Operating cash flow -105.58M
ESG Scores unknown

Company description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-06-30 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 158.92k 163.77k 7.82M 2.85M
Total Cashflows From Investing Activities -80.16M -80.16M -34.45M -54.12M
Net Borrowings -285.17k -368.69k -110.25k
Total Cash From Financing Activities 17.48M 126.11M 28.47M 187.94M
Change To Operating Activities 1.52M -26.46k 3.03M -10.71M
Issuance Of Stock 17.76M 126.48M 28.58M 187.94M
Net Income -17.32M -15.01M -59.46M -125.75M
Change In Cash 6.98M 33.85M -33.78M 41.95M
Effect Of Exchange Rate
Total Cash From Operating Activities -10.5M -12.09M -27.81M -91.87M
Depreciation 4.87k 4.36k 3.75k 1.26k
Change To Account Receivables -169.36k
Other Cashflows From Financing Activities
Change To Netincome 4.65M 2.77M 20.79M 41.74M
Capital Expenditures

Income Statement 2019-06-30 2019-12-31 2020-12-31 2021-12-31
Research Development 7.02M 7.86M 34.47M 90.62M
Income Before Tax -17.32M -15.01M -59.46M -125.75M
Net Income -17.32M -15.01M -59.46M -125.75M
Selling General Administrative 4.6M 7.25M 24.87M 35.08M
Gross Profit
Ebit -11.62M -15.11M -59.34M -125.7M
Operating Income -11.62M -15.11M -59.34M -125.7M
Interest Expense -761.04k
Income Tax Expense
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet -5.7M 104.11k -117.72k -48.32k
Net Income From Continuing Ops -17.32M -15.01M -59.46M -125.75M
Net Income Applicable To Common Shares -17.32M -15.01M -59.46M -125.75M

Balance Sheet Statement 2019-06-30 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.61M 1.46M 12.6M 15.06M
Total Stockholder Equity 7.61M 115.68M 105.58M 208.26M
Other Current Liabilities 500k 250k
Total Assets 10.22M 117.14M 118.19M 223.33M
Common Stock 9.74k 14.46k 16.33k 27.74k
Other Current Assets
Retained Earnings -111.66M -119.86M -179.32M -305.07M
Treasury Stock
Cash 9.22M 36.28M 2.5M 44.44M
Total Current Liabilities 2.61M 1.46M 12.6M 15.06M
Other Stockholder Equity
Property, Plant, and Equipment 7.21k 5.01k 1.26k
Total Current Assets 9.98M 116.94M 118.07M 223.3M
Net Tangible Assets 7.61M 115.68M 105.58M 208.26M
Net Receivables 247.08k 73.09k 79.46k 86.38k
Accounts Payable 924.36k 522.66k 8.35M 11.19M


Insider Transactions

Here are the insider transactions of stock shares related to Relmada Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
TRAVERSA SERGIOSale at price 18.32 - 19.37 per share.D2022-07-01Chief Executive Officer29.77k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 16.00 per share.D2022-07-01Chief Executive Officer29.77k
KELLY PAUL EDWARDSale at price 30.04 per share.D2022-04-04Director10k
KELLY PAUL EDWARDConversion of Exercise of derivative security at price 3.24 per share.D2022-04-04Director10k
CASAMENTO CHARLES JSale at price 29.00 per share.D2022-04-01Director19.8k
CASAMENTO CHARLES JConversion of Exercise of derivative security at price 3.24 per share.D2022-04-01Director19.8k
KELLY PAUL EDWARDConversion of Exercise of derivative security at price 3.24 per share.D2022-01-03Director20k
CASAMENTO CHARLES JSale at price 29.00 per share.D2021-09-22Director6.6k
CASAMENTO CHARLES JConversion of Exercise of derivative security at price 4.60 per share.D2021-09-22Director10k
CASAMENTO CHARLES JConversion of Exercise of derivative security at price 4.60 per share.D2021-08-17Director10k
CASAMENTO CHARLES JSale at price 31.03 - 32.49 per share.D2021-07-15Director3.3k
CASAMENTO CHARLES JSale at price 33.19 - 34.08 per share.D2021-06-01Director3k
CASAMENTO CHARLES JSale at price 38.22 per share.D2021-05-03Director3k
CASAMENTO CHARLES JSale at price 35.04 - 35.93 per share.D2021-04-01Director3k
TRAVERSA SERGIOSale at price 35.09 - 36.32 per share.D2021-03-10Chief Executive Officer10k
SHENOUDA MAGED RSale at price 35.00 - 36.02 per share.D2021-03-10Chief Financial Officer10k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 3.24 per share.D2021-03-09Chief Executive Officer10k
KELLY PAUL EDWARDSale at price 35.42 - 36.33 per share.D2021-03-09Director5k
KELLY PAUL EDWARDConversion of Exercise of derivative security at price 3.24 per share.D2021-03-09Director5k
SHENOUDA MAGED RConversion of Exercise of derivative security at price 3.24 per share.D2021-03-08Chief Financial Officer10k
CASAMENTO CHARLES JSale at price 33.87 per share.D2021-03-01Director3k
TRAVERSA SERGIOSale at price 33.69 - 35.55 per share.D2021-02-24Chief Executive Officer10k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 3.24 per share.D2021-02-24Chief Executive Officer10k
SHENOUDA MAGED RSale at price 33.74 - 34.67 per share.D2021-02-24Chief Financial Officer3k
SHENOUDA MAGED RConversion of Exercise of derivative security at price 3.24 per share.D2021-02-24Chief Financial Officer3k
KELLY PAUL EDWARDSale at price 33.67 - 35.58 per share.D2021-02-24Director5k
KELLY PAUL EDWARDConversion of Exercise of derivative security at price 3.24 per share.D2021-02-24Director5k
KELLY PAUL EDWARDConversion of Exercise of derivative security at price 6.00 per share.D2021-02-16Director5k
TRAVERSA SERGIOSale at price 35.43 per share.D2021-02-11Chief Executive Officer1.45k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 3.24 per share.D2021-02-11Chief Executive Officer1.45k
SHENOUDA MAGED RSale at price 35.39 per share.D2021-02-11Chief Financial Officer1.43k
SHENOUDA MAGED RConversion of Exercise of derivative security at price 3.24 per share.D2021-02-11Chief Financial Officer1.43k
TRAVERSA SERGIOSale at price 35.03 - 35.28 per share.D2021-02-10Chief Executive Officer11.21k
SHENOUDA MAGED RSale at price 35.04 - 35.24 per share.D2021-02-10Chief Financial Officer11.37k
KELLY PAUL EDWARDSale at price 35.04 - 35.28 per share.D2021-02-09Director3.57k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 3.24 per share.D2021-02-08Chief Executive Officer11.21k
SHENOUDA MAGED RConversion of Exercise of derivative security at price 3.24 per share.D2021-02-08Chief Financial Officer11.37k
KELLY PAUL EDWARDConversion of Exercise of derivative security at price 3.24 per share.D2021-02-08Director3.57k
TRAVERSA SERGIOSale at price 35.00 - 35.08 per share.D2021-02-03Chief Executive Officer3.28k
SHENOUDA MAGED RSale at price 35.00 - 35.04 per share.D2021-02-03Chief Financial Officer3.2k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 3.24 per share.D2021-02-02Chief Executive Officer3.28k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 3.24 per share.D2021-02-02Chief Executive Officer13.28k
SHENOUDA MAGED RConversion of Exercise of derivative security at price 3.24 per share.D2021-02-02Chief Financial Officer3.2k
KELLY PAUL EDWARDSale at price 35.00 - 35.04 per share.D2021-02-02Director2.35k
CASAMENTO CHARLES JSale at price 33.30 - 33.90 per share.D2021-02-01Director3k
KELLY PAUL EDWARDConversion of Exercise of derivative security at price 3.24 per share.D2021-02-01Director17.35k
TRAVERSA SERGIOSale at price 31.77 - 33.43 per share.D2021-01-27Chief Executive Officer10k
TRAVERSA SERGIOConversion of Exercise of derivative security at price 3.24 per share.D2021-01-27Chief Executive Officer10k
SHENOUDA MAGED RSale at price 31.59 - 32.43 per share.D2021-01-27Chief Financial Officer3k
SHENOUDA MAGED RConversion of Exercise of derivative security at price 3.24 per share.D2021-01-27Chief Financial Officer3k
KELLY PAUL EDWARDSale at price 31.69 - 33.40 per share.D2021-01-27Director5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Relmada Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Relmada Therapeutics Inc

Here is the result of two systematic investment strategies applied to Relmada Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Relmada Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Relmada Therapeutics Inc:

Relmada Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 219.83% on the backtest period.

Performance at glance

Performance

219.83 %

Latent gain

4900.32 $

Invested capital

2229.18 $

Annualized return

53.1 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Relmada Therapeutics Inc

This is the result of two momentum investment strategies applied to Relmada Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Relmada Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Relmada Therapeutics Inc:

Relmada Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 297.84% of return on Relmada Therapeutics Inc. That represents 19541.57$ of latent gain with 6561.13$ of employed capital.
  • The second momentum investment strategy would give 180.31% of return on Relmada Therapeutics Inc. That represents 7637.22$ of latent gain with 4235.58$ of employed capital.
Performance at glance (1Q Momentum)

Performance

297.84 %

Latent gain

19541.57 $

Invested capital

6561.13 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

180.31 %

Latent gain

7637.22 $

Invested capital

4235.58 $

Annualized return

49.27 %

Momentum equity curve on Relmada Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Relmada Therapeutics Inc:

Relmada Therapeutics Inc momentum equity

Note: the dividends potentially given by Relmada Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Relmada Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Relmada Therapeutics Inc since the beginning:

Relmada Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Relmada Therapeutics Inc

Buy the dip entry openings on Relmada Therapeutics Inc

Relmada Therapeutics Inc

The performance achieved by the robo-advisor on Relmada Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Relmada Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Relmada Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Relmada Therapeutics Inc

The following chart shows the result of the investment strategy applied to Relmada Therapeutics Inc:

Relmada Therapeutics Inc

Note: the dividends potentially given by Relmada Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Relmada Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Relmada Therapeutics Inc:

Relmada Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Relmada Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Relmada Therapeutics Inc.

Equity curve comparison on Relmada Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Relmada Therapeutics Inc investment strategy comparison

Employed capital comparison on Relmada Therapeutics Inc

Relmada Therapeutics Inc investment comparison

Performance comparison on Relmada Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 219.83% 4900.32$ 2229.18$ 53.1%
Momentum 1 quarter 297.84% 19541.57$ 6561.13$ 76.37%
Momentum 2 quarters 180.31% 7637.22$ 4235.58$ 49.27%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

53.1 %

Momentum 1Q

49.27 %

Momentum 2Q

49.27 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Relmada Therapeutics Inc:

Note: The algorithm computes the probability of correlation between Relmada Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Relmada Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Relmada Therapeutics Inc
Country United States
City Coral Gables
Address 2222 Ponce de Leon Boulevard
Phone 786 629 1376
Website www.relmada.com
FullTime employees 10
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker RLMD
Market www.nasdaq.com

Relmada Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown